Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Brainsway ( (BWAY) ) has provided an announcement.
BrainsWay announced positive results from a study conducted at Stanford University, which tested an accelerated protocol of its Deep Transcranial Magnetic Stimulation (TMS) technology for treating alcohol use disorder (AUD). The pilot data revealed significant improvements in reducing heavy drinking and relapse rates among patients compared to other treatments. Following these promising findings, the National Institutes of Health awarded $1.5 million to further explore the efficacy of Deep TMS in treating substance use addictions, highlighting the technology’s potential impact in the addiction treatment space.
More about Brainsway
BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. It utilizes its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform to improve health and transform lives. The company has FDA clearance for major depressive disorder, obsessive-compulsive disorder, and smoking addiction. Founded in 2003, BrainsWay operates in Israel and the U.S., focusing on increasing global awareness and access to Deep TMS.
YTD Price Performance: 51.39%
Average Trading Volume: 92,752
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $184.3M
See more insights into BWAY stock on TipRanks’ Stock Analysis page.
